Latest Articlesddd
The high risk of premature death from cardiovascular disease is believed to be caused by an …
Stage III (locally-advanced) NSCLC is commonly divided into three sub-categories: IIIA, IIIB and IIIC, defined by …
The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …
While preparing The Week in Review issue from Prohost, our attention shifted towards historical news about …
Compugen Again On Sept 10, 2018, we posted in The Week in Review #28 news we found …
Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed …
Exelixis’ (EXEL) partner Ipsen Biopharmaceuticals Canada Inc. received approval of Cabometyx®(cabozantinib) tablets from Health Canada for adults with …
CRISPR Gene Editing Beyond Bringing Cures to disease-causing genes, CRISPR gene editing technology can change the way diseases …
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic …
Phase 2 clinical trial data of argenx’s (ARGX) product Efgartigimod (ARGX-113) in adult patients with primary immune …
Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX). The increased investors’ activity …
Gilead Sciences (GILD) has news that we felt good about it for a company that saved …
Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific …
In the Week in Review posted yesterday on our website that is experiencing several attempts on …
The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …
Gilead Sciences’ (GILD) and Galapagos’ (GLPG) product filgotinib – a highly selective JAK1 inhibitor has met …
The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer …
The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …
We reiterate that undeniably outstanding news about gene therapy is taking time to penetrate investors’ ears. …
A complete response letter (CRL) sent by The Division of Metabolism and Endocrinology Products of the …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
